Live Breaking News & Updates on Company Annamycin

Stay updated with breaking news from Company annamycin. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Moleculin Announces New Positive Independent Report of No Cardiotoxicity in Annamycin

– Annamycin continues to demonstrate no evidence of cardiotoxicity to date, now in a total of 62 subjects across three of the Company s Annamycin clinical trials
– Next generation anthracycline,. ....

United States , Walter Klemp , Jenene Thomas , Prnewswire Moleculin Biotech Inc , Exchange Commission , Company Annamycin , Moleculin Biotech Inc , Securities Exchange , Recommended Phase , Chief Executive Officer , Moleculin Biotech , Transcription Modulator , Securities Act , Securities Exchange Act , Private Securities Litigation Reform Act , Although Moleculin ,

Moleculin Reports 80% Overall Response Rate in Final Cohort of Phase 1 Single Agent Trial of Annamycin for the Treatment of Acute Myeloid Leukemia (AML)

Preliminary efficacy updated to 80% overall response rate (ORR) demonstrated in single agent AML trial following database lock Next generation anthracycline,. ....

United States , Jenene Thomas , Gill Shephard , Walter Klemp , Liposomal Annamycin , Company Annamycin , Moleculin Biotech Inc , Exchange Commission , American Society Of Hematology , Securities Exchange , Orphan Drug , Moleculin Biotech , American Society , Annual Meeting , Partial Response , Fast Track Status , Orphan Drug Designation , Transcription Modulator , Securities Act , Securities Exchange Act , Private Securities Litigation Reform Act , High Efficacy ,